Drug intelligence / Profile preview

IVS-5001

Development stage: Preclinical
Lead developer: Invectys
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**IVS-5001** is an investigational anti-ILT4 nanobody derived from immunoglobulins found in alpacas and camelids, developed by Invectys as part of their HLA-G immunotherapy platform. ILT4 (also known as LILRB2) is an inhibitory receptor on myeloid cells that suppresses immune responses in the tumor microenvironment. By targeting ILT4, IVS-5001 aims to reactivate antitumor immunity. It is being developed for glioblastoma and other solid tumors and is currently in preclinical development.[2][3][7]

Targets

LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)

Beyond the preview

Go deeper on IVS-5001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVS-5001.

Explore the full profile